Who Paid My Doc
Tara McNamara
Optometrist, Corneal and Contact Management Middletown, PA Doctor of Optometry
NPI 1730247909 CMS profile 896236
4000 Vine St, Middletown, PA 17057
General payments
$25
Research payments
$0
Ownership & investment interest
$0
Through program year 2019, Tara McNamara of Middletown, PA is reported in the CMS Open Payments database as having received $25 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 3rd percentile of Optometrist, Corneal and Contact Management profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $25 | 1 |
Beside peers
- Tara McNamara
- Optometrist, Corneal and Contact Management median
- Middle half of Optometrist, Corneal and Contact Management
- National median
In program year 2025, general payments to Tara McNamara were reported at $0. Among 618 Optometrist, Corneal and Contact Management profiles paid that year, the median was $227 and the middle half received between $95 and $604.
Show as a table
| Year | Tara McNamara | Optometrist, Corneal and Contact Management median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $25 | $203 | $84–$530 | $163 |
| 2020 | $0 | $88 | $35–$234 | $114 |
| 2021 | $0 | $143 | $54–$353 | $132 |
| 2022 | $0 | $167 | $65–$422 | $149 |
| 2023 | $0 | $195 | $76–$549 | $160 |
| 2024 | $0 | $202 | $85–$523 | $164 |
| 2025 | $0 | $227 | $95–$604 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
135
Drug cost
$1,477
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | Brand | 135 | $1,477 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Optometrist, Corneal and Contact Management in Pennsylvania
Monika Marczak
Optometrist, Corneal and Contact Management · McMurray, PA
John Boyle
Optometrist, Corneal and Contact Management · Scranton, PA
Cody Sherrin
Optometrist, Corneal and Contact Management · York, PA
Mary Nguyen
Optometrist, Corneal and Contact Management · Springfield, PA
Lowell Lebovitz
Optometrist, Corneal and Contact Management · Pittsburgh, PA
Sandy John
Optometrist, Corneal and Contact Management · Plymouth Meeting, PA
Related records
Optometrist, Corneal and Contact Management in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Optometrist, Corneal and Contact Management
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.